Analysts Issue Forecasts for BLFS Q1 Earnings

BioLife Solutions, Inc. (NASDAQ:BLFS) – Equities researchers at Northland Capmk issued their Q1 2026 earnings per share estimates for BioLife Solutions in a research report issued to clients and investors on Monday, January 5th. Northland Capmk analyst C. Byrnes forecasts that the medical equipment provider will earn $0.01 per share for the quarter. The consensus estimate for BioLife Solutions’ current full-year earnings is ($0.30) per share. Northland Capmk also issued estimates for BioLife Solutions’ Q2 2026 earnings at $0.02 EPS, Q3 2026 earnings at $0.03 EPS, Q4 2026 earnings at $0.03 EPS and FY2027 earnings at $0.25 EPS.

Other analysts also recently issued reports about the stock. HC Wainwright restated a “buy” rating and issued a $32.00 target price on shares of BioLife Solutions in a report on Monday, December 29th. Zacks Research cut BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 8th. Wall Street Zen downgraded BioLife Solutions from a “buy” rating to a “hold” rating in a research report on Sunday, November 30th. UBS Group reiterated a “buy” rating on shares of BioLife Solutions in a report on Monday, December 29th. Finally, Northland Securities set a $34.00 target price on BioLife Solutions in a research report on Monday. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $32.00.

BioLife Solutions Stock Down 3.7%

BioLife Solutions stock opened at $25.39 on Tuesday. BioLife Solutions has a 52-week low of $19.10 and a 52-week high of $29.62. The firm’s fifty day moving average is $25.51 and its 200 day moving average is $24.81. The company has a market cap of $1.22 billion, a price-to-earnings ratio of -362.62 and a beta of 1.93.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Comerica Bank lifted its position in shares of BioLife Solutions by 5.2% in the 1st quarter. Comerica Bank now owns 15,024 shares of the medical equipment provider’s stock worth $343,000 after purchasing an additional 746 shares during the period. State of Wyoming lifted its holdings in BioLife Solutions by 353.1% during the first quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider’s stock worth $44,000 after buying an additional 1,490 shares during the period. Royal Bank of Canada lifted its holdings in BioLife Solutions by 762.8% during the first quarter. Royal Bank of Canada now owns 698,251 shares of the medical equipment provider’s stock worth $15,948,000 after buying an additional 617,320 shares during the period. Jacobs Levy Equity Management Inc. bought a new stake in BioLife Solutions during the 1st quarter valued at $283,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of BioLife Solutions by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,422 shares of the medical equipment provider’s stock valued at $489,000 after acquiring an additional 914 shares during the period. Hedge funds and other institutional investors own 93.24% of the company’s stock.

Insider Transactions at BioLife Solutions

In other BioLife Solutions news, CFO Troy Wichterman sold 1,033 shares of the company’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $25.13, for a total value of $25,959.29. Following the completion of the sale, the chief financial officer directly owned 151,736 shares in the company, valued at approximately $3,813,125.68. This represents a 0.68% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Greef Roderick De sold 31,165 shares of the stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $25.33, for a total value of $789,409.45. Following the transaction, the chief executive officer directly owned 389,998 shares in the company, valued at $9,878,649.34. The trade was a 7.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 935,426 shares of company stock valued at $26,250,077. Company insiders own 2.20% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.